Bites of Bio

Topic

Cell & Molecular Biology

KRAS in pancreatic cancer: why it is so hard to targetCancer & Oncology
Sep 25, 2026

KRAS in pancreatic cancer: why it is so hard to target

KRAS mutations drive more than 90% of pancreatic ductal adenocarcinomas (PDAC), yet the protein resisted direct drug development for decades because its surface offered few stable pockets for small molecules and because the mutant protein cycles between active and inactive conformations. That biology is now clinically relevant: a phase 3 trial published in The New […]

Read the Full Bite →